NRx Pharmaceuticals, Inc. (NRXP) P/E Ratio History
Historical price-to-earnings valuation from 2018 to 2019
Loading P/E history...
NRXP Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, NRx Pharmaceuticals, Inc. (NRXP) trades at a price-to-earnings ratio of -2.3x, with a stock price of $3.06 and trailing twelve-month earnings per share of $-1.71.
The current P/E is 100% below its 5-year average of 1651.0x. Over the past five years, NRXP's P/E has ranged from a low of 645.9x to a high of 4096.4x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, NRXP trades at a 110% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, NRXP trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our NRXP DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
NRXP P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $351M | 28.4 | -Best | +120%Best | |
| $151B | 19.5Lowest | -Best | -4% | |
| $536B | 38.4 | -Best | -58% | |
| $358B | 85.5 | -Best | -1% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
NRXP Historical P/E Data (2018–2019)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2019 Q3 | Mon Sep 30 2019 00:00:00 GM | $105.80 | $0.16 | 645.9x | -61% |
| FY2019 Q2 | Sun Jun 30 2019 00:00:00 GM | $105.30 | $0.15 | 686.4x | -58% |
| FY2019 Q1 | Sun Mar 31 2019 00:00:00 GM | $103.30 | $0.09 | 1175.2x | -29% |
| FY2018 Q4 | Mon Dec 31 2018 00:00:00 GM | $102.00 | $0.02 | 4096.4x | +148% |
Average P/E for displayed period: 1651.0x
See NRXP's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NRXP Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare NRXP vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonNRXP — Frequently Asked Questions
Quick answers to the most common questions about buying NRXP stock.
Is NRXP stock overvalued or undervalued?
NRXP trades at -2.3x P/E, below its 5-year average of 1651.0x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does NRXP's valuation compare to peers?
NRx Pharmaceuticals, Inc. P/E of -2.3x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is NRXP's PEG ratio?
NRXP PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2018-2019.